Compare Starbucks Corp (SBUX) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Starbucks Corp vs TG Therapeutics Inc — how do they compare? Starbucks Corp trades at $90.87 (market cap $106.26B), while TG Therapeutics Inc trades at $55 (market cap $8.16B). The key difference: Starbucks Corp is far larger — about 13× TG Therapeutics Inc's market cap, and Starbucks Corp pays a 2.7% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Starbucks Corp for 190 Days and TG Therapeutics Inc for 16 Days on average.
| SBUX | TGTX | |
|---|---|---|
Market Cap | $106.26B | $8.16B |
Volume | 30,248,434 | 1,735,121 |
Sector | Consumer Cyclical | Health |
52-Week High | $108.55 | $59.06 |
52-Week Low | $78.46 | $26.94 |
Typical Hold Time | 190 Days | 16 Days |
Enterprise Value | $125.08B | $8.37B |
Dividend Yield | 2.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Starbucks (SBUX) trades at $90.75, down 3.02% today, amid a bearish technical outlook and mixed fundamental performance. The company reported Q2 2026 EPS beat ($0.85 vs. $0.66 expected) but missed in Q4 2025, with revenue growth slowing to 2.8% year-over-year in 2025. Recent news highlights store closures (250 locations) and strategic portfolio reset, while analyst consensus remains positive with a $115.50 price target. Negative shareholder equity and elevated debt levels present financial concerns.
Outlook: Near-term pressure from restructuring and geopolitical risks, but long-term growth potential in high-performing locations and international markets. Risks include execution on store strategy, labor relations, and China exposure. Investment case hinges on successful turnaround and margin recovery.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
